• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    11/6/23 12:31:09 PM ET
    $ALRN
    $CADL
    $CDIO
    $EVLO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALRN alert in real time by email

    Gainers

    • MSP Recovery (NASDAQ:LIFW) shares moved upwards by 481.0% to $15.92 during Monday's regular session. MSP Recovery's stock is trading at a volume of 44.7 million shares as of 12:30 EST. This is 2105.5% of its average full-day volume over the last 100 days. The company's market cap stands at $213.3 million.
    • Cardio Diagnostics Hldgs (NASDAQ:CDIO) shares moved upwards by 64.26% to $0.61. Cardio Diagnostics Hldgs's stock is trading at a volume of 69.7 million shares as of 12:30 EST. This is 1967.8% of its average full-day volume over the last 100 days. The company's market cap stands at $11.5 million.
    • Aileron Therapeutics (NASDAQ:ALRN) stock moved upwards by 26.29% to $1.47. Trading volume for Aileron Therapeutics's stock is 496.4K as of 12:30 EST. This is 1677.1% of its average full-day volume over the last 100 days. The company's market cap stands at $7.1 million.
    • Candel Therapeutics (NASDAQ:CADL) shares rose 25.9% to $0.85. As of 12:30 EST, Candel Therapeutics's stock is trading at a volume of 62.8K, which is 262.1% of its average full-day volume over the last 100 days. The company's market cap stands at $24.5 million.
    • Synlogic (NASDAQ:SYBX) shares increased by 25.8% to $2.34. The company's market cap stands at $19.8 million.
    • PaxMedica (NASDAQ:PXMD) shares moved upwards by 23.08% to $3.2. As of 12:30 EST, this security is trading at a volume of 447.0K shares, making up 345.4% of its average full-day volume over the last 100 days. The company's market cap stands at $3.2 million.

    Losers

    • Novo Integrated Sciences (NASDAQ:NVOS) shares fell 56.4% to $0.13 during Monday's regular session. As of 12:30 EST, this security is trading at a volume of 59.4 million shares, making up 101.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $21.8 million.
    • Zentalis Pharma (NASDAQ:ZNTL) stock declined by 24.89% to $13.43. As of 12:30 EST, this security is trading at a volume of 1.5 million shares, making up 226.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $948.2 million. As per the news, the Q3 earnings report came out today.
    • MoonLake (NASDAQ:MLTX) stock declined by 23.36% to $39.3. MoonLake's stock is trading at a volume of 3.5 million shares as of 12:30 EST. This is 685.7% of its average full-day volume over the last 100 days. The company's market cap stands at $2.1 billion.
    • Evelo Biosciences (NASDAQ:EVLO) stock declined by 19.98% to $0.34. Trading volume for Evelo Biosciences's stock is 1.4 million as of 12:30 EST. This is 391.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $6.4 million.
    • Oncology Institute (NASDAQ:TOI) shares fell 18.29% to $1.65. As of 12:30 EST, Oncology Institute's stock is trading at a volume of 259.5K, which is 129.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $120.4 million.
    • Organovo Holdings (NASDAQ:ONVO) shares decreased by 18.24% to $1.39. Trading volume for this security as of 12:30 EST is 174.0K, which is 393.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $12.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALRN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALRN
    $CADL
    $CDIO
    $EVLO

    CompanyDatePrice TargetRatingAnalyst
    MoonLake Immunotherapeutics
    $MLTX
    3/19/2026$40.00Neutral → Buy
    Rothschild & Co Redburn
    Zentalis Pharmaceuticals Inc.
    $ZNTL
    3/17/2026$5.00Equal Weight
    Wells Fargo
    MoonLake Immunotherapeutics
    $MLTX
    1/15/2026$10.00Neutral → Sell
    Goldman
    MoonLake Immunotherapeutics
    $MLTX
    1/9/2026$24.00Neutral → Buy
    BTIG Research
    The Oncology Institute Inc.
    $TOI
    11/25/2025$5.00Buy
    Needham
    MoonLake Immunotherapeutics
    $MLTX
    11/3/2025$30.00Neutral → Buy
    H.C. Wainwright
    Candel Therapeutics Inc.
    $CADL
    10/28/2025$15.00Overweight
    Stephens
    MoonLake Immunotherapeutics
    $MLTX
    10/2/2025Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $ALRN
    $CADL
    $CDIO
    $EVLO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    MoonLake Immunotherapeutics upgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn upgraded MoonLake Immunotherapeutics from Neutral to Buy and set a new price target of $40.00

    3/19/26 8:23:34 AM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo resumed coverage on Zentalis Pharma with a new price target

    Wells Fargo resumed coverage of Zentalis Pharma with a rating of Equal Weight and set a new price target of $5.00

    3/17/26 9:31:05 AM ET
    $ZNTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MoonLake Immunotherapeutics downgraded by Goldman with a new price target

    Goldman downgraded MoonLake Immunotherapeutics from Neutral to Sell and set a new price target of $10.00

    1/15/26 8:33:55 AM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALRN
    $CADL
    $CDIO
    $EVLO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026

    Preclinical evidence supports azenosertib ADC combinations as potential promising therapeutic strategies for Triple-Negative Breast Cancer  Demonstration of Cyclin E1 protein overexpression as an indicator for poor prognosis in ovarian cancer patients with real world data  SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced two poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April 17-22, 202

    3/17/26 4:30:00 PM ET
    $ZNTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

    Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with advanced non-small cell lung cancer (NSCLC) treated with aglatimagene besadenovec (aglatimagene or CAN-2409) surviving beyond 24 months, despite prior inadequate response to immune checkpoint inhibitors (ICI) and multiple adverse baseline prognostic factors.Among the patients surviving beyond 24 months and with PD-L1 status available, (17/20) 85% had baseline PD-L1 tumor proportion scores (TPS) below 50% (a population typically less responsive to ICI), supporting the potential of aglatimagene to upregulate PD-L1 in the tumor microenvironment and convert

    3/17/26 8:05:00 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    The Oncology Institute Reports Fourth Quarter and Full Year 2025 Financial Results and Guidance for 2026

    CERRITOS, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended December 31, 2025. Recent Operational Highlights Cash flow from operations in Q4 2025 was approximately $3.2 million, due to disciplined working capital management and overall increase in gross profit marginContinued expansion of our capitated footprint, initiating 9 new capitated contracts during 2025 in CA, FL, and NV, representing approximately 260,000 additional lives under managementFurther ramped our capitation

    3/12/26 4:05:00 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $ALRN
    $CADL
    $CDIO
    $EVLO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by The Oncology Institute Inc.

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    3/18/26 5:21:35 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by The Oncology Institute Inc.

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    3/18/26 5:19:09 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by The Oncology Institute Inc.

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    3/18/26 5:20:19 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $ALRN
    $CADL
    $CDIO
    $EVLO
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Candel Therapeutics Inc.

    SCHEDULE 13D/A - Candel Therapeutics, Inc. (0001841387) (Subject)

    3/18/26 4:23:14 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Cardio Diagnostics Holdings Inc.

    10-K - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

    3/13/26 5:18:52 PM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    The Oncology Institute Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Oncology Institute, Inc. (0001799191) (Filer)

    3/13/26 5:16:58 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $ALRN
    $CADL
    $CDIO
    $EVLO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Chernett Jorey bought $1,225,101 worth of shares (398,985 units at $3.07), increasing direct ownership by 4% to 10,251,929 units (SEC Form 4)

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    3/17/26 7:40:00 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Director Manning Paul B bought $2,999,996 worth of shares (550,458 units at $5.45) (SEC Form 4)

    4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

    2/26/26 7:38:59 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Walters Group bought $7,751,968 worth of shares (6,459,973 units at $1.20) (SEC Form 4)

    4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)

    1/8/26 4:57:05 PM ET
    $ZNTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALRN
    $CADL
    $CDIO
    $EVLO
    Leadership Updates

    Live Leadership Updates

    View All

    The Oncology Institute Appoints Kim Tzoumakas to Board of Directors

    CERRITOS, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced the appointment of Kim Tzoumakas to its Board of Directors, effective February 23, 2026. Ms. Tzoumakas brings more than two decades of executive leadership experience across oncology, pharmacy services and healthcare operations. Notably, she is Chief Executive Officer for VytlOne National Pharmacy Services, and previously held the CEO role at 21st Century Oncology, where she successfully led the organization through a multi-year operational turnaround, culminating in its strategic sale. She also has serve

    2/23/26 8:00:00 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

    Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene's clinical organization and drive completion of the Phase 2b ADAPTIVE trial in atopic dermatitis Will expand Phase 2b trial footprint with planned international sites including in the UK and Europe SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA, "Imagene, " or the "Company")), today announced the appointment of Dr. Ben Porter-Brown, a seasoned autoimmune and inflammatory drug developer with experience in the OX40 receptor-ligand (OX40-OX40L) inhibition field, as its Chief Medical Officer. He will be fo

    2/10/26 7:00:00 AM ET
    $IMA
    $MLTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    The Oncology Institute Announces Addition of Board Member Mark Stolper

    CERRITOS, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Mark Stolper has joined the Board of Directors, effective January 2, 2026. Mr. Stolper brings significant public markets, financial and operational leadership experience to The Oncology Institute's board. Mr. Stolper serves as Executive Vice President and Chief Financial Officer of RadNet, Inc. (NASDAQ:RDNT), a position he has held since 2004. Mr. Stolper has also been a member of the Board of Directors of various publicly traded and privately held healthcare companies, including 21st Century Oncolog

    1/5/26 8:30:00 AM ET
    $RDNT
    $TOI
    Medical Specialities
    Health Care
    Medical/Nursing Services

    $ALRN
    $CADL
    $CDIO
    $EVLO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MSP Recovery Inc.

    SC 13D/A - MSP Recovery, Inc. (0001802450) (Subject)

    12/17/24 4:05:04 PM ET
    $LIFW
    EDP Services
    Technology

    SEC Form SC 13G filed by Candel Therapeutics Inc.

    SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)

    12/17/24 12:30:40 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by PaxMedica Inc.

    SC 13G/A - PaxMedica, Inc. (0001811623) (Subject)

    11/14/24 7:22:38 PM ET
    $PXMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $ALRN
    $CADL
    $CDIO
    $EVLO
    Financials

    Live finance-specific insights

    View All

    The Oncology Institute Reports Fourth Quarter and Full Year 2025 Financial Results and Guidance for 2026

    CERRITOS, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended December 31, 2025. Recent Operational Highlights Cash flow from operations in Q4 2025 was approximately $3.2 million, due to disciplined working capital management and overall increase in gross profit marginContinued expansion of our capitated footprint, initiating 9 new capitated contracts during 2025 in CA, FL, and NV, representing approximately 260,000 additional lives under managementFurther ramped our capitation

    3/12/26 4:05:00 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    The Oncology Institute Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Conference Call

    CERRITOS, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI)  a pioneer in value-based community oncology care, today announced that the company will release its fourth quarter and full year 2025 financial results on Thursday, March 12, 2026, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 13758646. The

    2/26/26 8:00:00 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Cardio Diagnostics Holdings, Inc. to Host Investor Call on Wednesday, February 18, 2026

    Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) ("Cardio Diagnostics" or the "Company"), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, today announced that it will host an investor conference call on Wednesday, February 18, 2026, at 3 p.m. Central Time. The call will provide an overview of the Company's precision molecular approach to cardiovascular disease prevention and early detection, including updates on its commercially available tests, Epi+Gen CHD™ and PrecisionCHD™, recent breakthrough clinical data, reimbursement progress, and strategic growth initiatives. Web

    2/17/26 8:35:00 AM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care